Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cargo Therapeutics Inc.
Headquarters: San Mateo, CA, United States of America
Website: https://cargo-tx.com/
Year Founded: 2021
Status: Public
Industry Sector: HealthTechnology
CEO: Anup Radhakrishnan
Number Of Employees: 167
Enterprise Value: $353,654,908
PE Ratio: -1.11
Exchange/Ticker 1: NASDAQ:CRGX
Exchange/Ticker 2: N/A
Latest Market Cap: $192,038,496
See Emerging Company Profile .
BioCentury | Mar 20, 2025
Management Tracks
C-suite exits as Cargo and Elevation restructure
Plus: Hyku names Keith Wilcoxen CSO and new CMO at Immuneering
BioCentury | Feb 6, 2025
Product Development
Cardiometabolic wins among highlights in BioCentury’s latest Clinical Report
Plus readouts from Allakos, Leap, Cargo and more
BioCentury | Nov 21, 2024
Product Development
Companies get creative with multi-targeted CARs at SITC, ASH
BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts
BioCentury | Jun 6, 2024
Discovery & Translation
Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more
BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | Mar 7, 2024
Discovery & Translation
Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
BioCentury | Nov 14, 2023
Product Development
POC for Verve? Plus IRA & East-West deals: a BioCentury podcast
A first for in vivo base editing therapy is met with investor disappointment
BioCentury | Nov 10, 2023
Product Development
Nov. 10 Quick Takes: Cargo biggest biotech IPO to dip on first day
Plus: Madrigal identifies non-invasive efficacy assessment for NASH and updates from Novo and Valneva
Items per page:
1 - 10 of 20